A randomised, double-blind, parallel-group comparison of venlafaxine and dothiepin in geriatric patients with major depression

International Journal of Clinical Practice

Volumn 51, Issue 4, 1997, Pages 209-213

  Mahapatra, S N ^a   Hackett, D ^b,c  

^a Hartlepool and E Durham Gen Hosp   (United Kingdom)

^b Wyeth Clin Research and Development   (France)

^c Wyeth CRD   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DOSULEPIN; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DYSURIA; FEMALE; GERIATRIC PATIENT; HEADACHE; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NETHERLANDS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; UNITED KINGDOM; VERTIGO; XEROSTOMIA;

AGED; AGED, 80 AND OVER; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIDEPRESSIVE AGENTS, TRICYCLIC; CYCLOHEXANOLS; DEPRESSIVE DISORDER; DOTHIEPIN; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 0030847534     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Gurland BJ, Meyers BS. Geriatric psychiatry. In: Talbott JA, Hales RE, Yudofsky SC, Eds. Textbook of Psychiatry. Washington DC: American Psychiatric Press, 1988, 1117-1139.
2. Cunningham LA. Depression in the medically ill: choosing an antidepressant. J Clin Psychiat 1994; 55(Suppl A): 90-97.
3. Glassman AH, Roose SP. Risks of antidepressants in the elderly: tricyclic antidepressants and arrhythmia - revising risks. Gerontology 1994; 40(Suppl 1): 15-20.
4. Lane RM, Sweeney M, Henry JA. Pharmacotherapy of the depressed patient with cardiovascular and/or cerebrovascular illness. Br J Clin Pract 1994; 48: 256-262.
5. Preskorn SH, Fast GA. Therapeutic drug monitoring for antidepressants: efficacy, safety, and cost-effectiveness. J Clin Psychiat 1991; 52(Suppl): 23-33.
6. Ray WA, Griffin MR, Schaffner W et al. Psychotropic drug use and the risk of hip fracture. N Engl J Med 1987; 316: 363-369.
7. Dollery C. Therapeutic Drugs. Edinburgh: Churchill Livingstone, 1991.
8. Muth EA, Haskins JT, Moyer JA et al. Antidepressant profile of the novel bicyclic compound WY-45,030, an ethylcyclohexanol derivative. Biochem Pharmacol 1986; 35: 4493-4497.
9. Muth EA, Moyer JA, Haskins JT et al. Biochemical, neurophysiological, and behavioral effects of WY-45,233 and other identified metabolites of the antidepressant venlafaxine. Drug Dev Res 1991; 23: 191-199.
10. Benkert O, Grunder G, Wetzel H, Hackett D. A randomized, double-blind comparison of a rapidly escalating dose of venlafaxine and imipramine in inpatients with major depression and melancholia. J Psychiatr Res 1996; 30(4): 441-451.
11. Schweizer E, Feighner J, Mandos L, Rickels K. Comparison of venlafaxine and imipramine in the acute treatment of major depression in outpatients. J Clin Psychiat 1994; 55: 104-108.
12. Shrivastava R, Cohn C, Crowder J et al. Long-term safety and clinical acceptability of venlafaxine and imipramine in patients with major depression. J Clin Psychopharmacol 1994; 14: 99-106.
13. Lecrubier Y, Moon CAL, Schifano F et al. Double-blind, randomized, placebo-controlled comparison of venlafaxine and imipramine in general practice patients with rnild to moderate depression. Acta Psych Scand 1997. In press.
14. Khan A, Rudolph R, Baumel B et al. Venlafaxine in depressed geriatric outpatients: an open-label clinical study. Psychopharmacol Bull 1995; 31: 753-758.
15. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiat 1960; 23: 56-62.
16. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiat 1979; 134: 382-389.
17. Guy W. ECDEU Assessment Manual for Psychopharmacology. DHEW Pub. No. (ADM)76-338, Rockville, MD: NIMH, 1976.
18. Clerc GE, Ruimy P, Verdeau-Pailes J. A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. Int Clin Psychopharmacol 1994; 9: 138-143.
19. Cunningham LA, Borison RL, Carman JS et al. A comparison of venlafaxine, trazodone, and placebo in major depression. J Clin Psychopharmacol 1994; 14: 99-106.
20. Dierick M, Ravizza L, Martin A, Realini R. A double-blind comparison of venlafaxine and fluoxetine for treatment of major depression in outpatients. Prog Neuropsychopharmacol 1996; 20: 57-71.
21. Preskorn SH. Antidepressant drug selection: criteria and options. J Clin Psychiat 1994; 55:9(Suppl): 6-22.
22. Preskorn SH, Jerkovich GS. Central nervous system toxicity of tricyclic antidepressants: phenomenology, course, risk factors, and role of therapeutic drug monitoring. J Clin Psychopharmacol 1990; 10: 88-94.
23. Preskorn SH, Othmer S, Lai C et al. Tricyclic antidepressants and delirium. J Clin Psychiat 1982; 139: 822-823.
24. Preskorn SH, Fast GH. Tricyclic antidepressant-induced seizures and plasma drug concentration. J Clin Psychiat 1992; 53: 160-162.
25. Petit JM, Spiker DG, Ruwitch JF et al. Tricyclic antidepressant plasma levels and adverse effects after overdose. Clin Pharmacol Ther 1977; 21: 47-51.
26. Rudorfer MB, Young RC. Desipramine: cardiovascular effects and plasma levels. Am J Psychiat 1980; 137: 984-986.
27. Veith RC, Friedel RO, Bloom B et al. Electrocardiogram changes and plasma desipramine levels during treatment. Clin Pharmacol Ther 1980; 27: 796-802.
28. Preskorn SH, Weller E, Weller R et al. Plasma levels of imipramine and adverse effects in children. Am J Psychiat 1983; 140: 1332-1335.
29. Preskorn SH, Irwin HA. Toxicity of tricyclic antidepressants: kinetics mechanism, intervention: a review. J Clin Psychiat 1982; 43: 151-156.
30. Vohra J, Burrows G, Hunt D. The effects of toxic and therapeutic doses of tricyclic antidepressant drugs on intracardiac conduction. Eur J Cardiol 1975; 3: 219-227.
31. Roose SP, Glassman AH, Attia A, Woodring SP. Comparative efficacy of selective serotonin reuptake inhibitors and tricyclics in the treatment of melancholia. Am J Psychiat 1994; 151: 1735-1739.
32. Danish University Antidepressant Group. Citalopram: clinical effect profile in comparison with clomipramine: a controlled multicenter study. Psychopharmacolony 1986; 90: 131-138.
33. Danish University Antidepressant Group. Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. J Affect Disord 1990; 18: 289-299.
34. Danjou P, Hackett D. Safety and tolerance profile of venlafaxine. Int Clin Psychopharmacol 1995; 10(Suppl 2): 15-20.